From: Oral health and HIV infection among female sex workers in Abidjan, Côte d’Ivoire
N = 84 | (%) | |
---|---|---|
Type of HIV | ||
HIV-1 | 82 | (97.6) |
HIV-1 + 2 dually infected patients | 2 | (2.4) |
Time since first positive HIV serology, Median [IQR]≠ (years) | 4.1 | [1 5.7] |
ARTβ use, | ||
Yes | 69 | (82.1) |
No | 15 | (17.9) |
ART regimena | ||
Zidovudine/Lamivudine/Nevirapine | 45 | (65.2) |
Zidovudine/Lamivudine/Efavirenz | 4 | (5.8) |
Zidovudine/Lamivudine/Lopinavir/Ritonavir | 1 | (1.5) |
Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz | 9 | (13.0) |
Tenofovir disoproxil fumarate/Lamivudine/Efavirenz | 6 | (8.7) |
Tenofovir disoproxil fumarate/Emtricitabine/Nevirapine | 4 | (5.8) |
CD4 count† - Median [IQR] in cells/mm3 | 366 | [260 545] |
On ART (n = 69) | 338 | [97 459] |
No ART (n = 15) | 649 | [504 825] |
CDC Clinical stage∫ | ||
Stage A | 29 | (34.5) |
Stage B | 39 | (46.4) |
Stage C (AIDS) | 16 | (19.1) |